fibrinogen

Fibrinogen is a heterodimeric protein that can be cleaved by thrombin. Fibrinogen is a potential marker for cardiovascular disease and plays an important role in metabolism. Its absence can cause fibrinogenemia.

Bovine fibrinogen (from fibrinogen) is a natural fibrinogen derived from bovine plasma. It can modulate the activation of NF-KB in endothelial cells and upregulate the expression of the inflammatory chemokine MCP-1.

Fibrinogen (from human plasma) is suitable for preparing production factor solutions.

Fibrinogen from rat plasma can be used for the preparation of growth factor solutions.

Heparin (Nadroparin) calcium (MW 3600-5000), an anticoagulant, forms a reversible complex with antithrombin III (ATIII), known as the heparin-antithrombin III complex. This complex then irreversibly binds to and inactivates thrombin and other activated clotting factors IX, X, XI, and XII, thereby inhibiting the conversion of fibrinogen to fibrin [1] [2].

Bemiltenase alfa is a hemostatic agent that targets coagulation factor X (FX). It activates FX to facilitate the conversion of prothrombin into thrombin, which subsequently transforms fibrinogen into fibrin, thereby forming a stable blood clot and exerting its hemostatic effect. Bemiltenase alfa shows potential for research in bleeding symptoms associated with hemophilia.

Nonacog gamma is a coagulation factor IX (FIX) supplement that activates factor X (FX), facilitating the generation of thrombin, which then converts fibrinogen into fibrin to form a stable blood clot and exert hemostatic effects. Nonacog gamma holds potential for research in the treatment of hemophilia B.

Human Tenascin is a glycoprotein capable of forming hexamers linked by disulfide bonds. It consists of repeated domains, including EGF-like repeats, fibronectin type III repeats, and regions homologous to fibrinogen. Human Tenascin is applicable for cell culture.

HumanFactor VIIa is a vitamin K-dependent serine protease involved in the blood coagulation process. It has the ability to activate coagulation factor X, which in turn converts prothrombin into thrombin, leading to the transformation of fibrinogen into fibrin and resulting in the formation of blood clots. HumanFactor VIIa holds potential for improving hemophilia.